Introduction

In humans, infection can result from a variety of organisms including bacteria, viruses, parasites and fungi. Traditionally, pathogenic infections were defined according to Koch’s postulates, i.e. they were organisms that could be ‘found’, isolated, cultured and confirmed as a causative agent of disease by inoculation into a new host. Apart from the obvious limitations of pathogen isolation and culture techniques, Koch’s postulates were criticized and adapted in the face of technological advances, such as the identification of pathogen-specific nucleic acids using molecular biology techniques. With the advent of metagenomic sequencing, it has become clear that the presence of a microbe is not necessarily indicative of pathogenesis and instead may represent a degree of co-evolution and symbiosis between the organism and the host. Accumulating evidence demonstrates that commensal organisms colonizing our mucosal surfaces, particularly the gut microbiome, benefit immune functions at all levels. However, opportunistic infections by commensal bacteria and fungi can also occur, usually in the hospital setting of patients who are already ill, resulting in severe nosocomial sepsis or pneumonia.

Chronic infections are either persistent or latent infections within a host. Despite attempts by the immune system to respond to the acute infection, pathogens escape from immune clearance by modulating, or regulating our immune response. For instance, persistence of an unresolved infection can result in immune exhaustion or deviation, for example, by switching of CD4+ T cells to interleukin-10 (IL-10) producers in patients with chronic hepatitis C virus (HCV) infection, or the induction of IL-10 and interferon-γ co-production by CD4+ T cells following parasitic Toxoplasma gondii infection. The hijacking of these pathways by pathogens is an effective way for viruses and parasites to avoid immunopathology while establishing a persistent or latent infection. In some instances, this immune regulation may also be coupled to significant benefits for the host, damping underlying inflammatory disorders and resulting in a survival advantage. Below we will consider examples of this mutualistic symbiosis, focusing on examples from chronic viral and parasitic infections.
Viruses

In the case of viruses, metagenomic sequencing of the ‘virome’ has identified eukaryotic viruses, including acute infections, chronic replicating infections and chronic latent infections. Furthermore, in a complex multicellular eukaryotic host, the virome also includes bacteriophages infecting the microbiota, and virus-derived genetic elements incorporated into eukaryotic chromosomes, e.g. retrovirus-encoded elements, which are thought to make up 8% of the genome. It is difficult to know how stably associated the overall virome is with the host, particularly as viruses relying solely on a lytic life cycle, such as influenza virus, respiratory syncytial virus or dengue virus, cause cell death but tend to produce short-lived acute infections. However, non-cytopathic viruses, which do not cause such profound cell death, can infect and persist for the lifespan of the host.

It is estimated that humans carry between 8 and 12 persistent viral infections, including herpesviruses, retroviruses, *Allenoviridae* and in fewer individuals: papillomaviruses, hepatitis viruses and human immunodeficiency virus (HIV). For most of the life-time of the host, persistent viral infections cause no overt clinical disease. This pathogen-induced immune regulation is also employed by other chronic infections, including parasites (discussed in the next section), to enhance pathogen survival and often confer a survival advantage to the host. This viral mutualistic symbiosis is well recognized in invertebrates and plants, for example infection with cucumber mosaic virus imparts drought resistance to the *Nicotiana benthamiana* plant. Some viruses operate through a bacterial go-between to exert a symbiotic effect, for example aphids are protected from invading wasp larvae by infection with a heritable symbiotic bacteria that harbours a bacteriophage encoding an anti-wasp toxin. In these examples, the virus alters gene expression in the host and confers an advantage, which in the case of a chronically infected host, results in an increased chance of competitiveness and survival.

So can we find examples of mutualistic symbiosis in human (or vertebrate) hosts? The success of the balance between the replication and survival of the invading virus and the immune response and survival of the host can be defined by four key clinical factors: does the presence of viral infection lead to tissue, and hence organ, dysfunction; does the virus compromise the immunity of the host allowing secondary pathogens to invade; conversely does the immune system maintain a state of persistent activation leading to immunopathology; and lastly, is it possible that a persistent viral infection may in some manner benefit the host?

Hepatotropic viruses illustrate the complexity of host–virus relationships. Although these viruses grow and replicate in the liver, some hepatotropic viruses spread by the oral–faecal route (hepatitis A virus and hepatitis E virus). They are adapted to rapid host-to-host horizontal spread by passing from the liver to the gut and the faeces, using the ideal conduit: the biliary tract. These viruses have no need to persist in humans. However, hepatitis B virus (HBV) and HCV are blood-borne infections, whose natural route of infection is perinatal, from the mother to the neonate. For these viruses, the chances of transmission are rarer, and to maximize the likelihood of success, an ideal scenario is persistent infection accompanied by high levels of viraemia. After initial infection with HCV, 80% of people develop chronic infection, exhibit detectable viraemia (ranging from about $10^3$ to $10^7$ copies/ml) but no evidence of liver disease. Both HBV and HCV have evolved a series of strategies to avoid or evade the innate and adaptive immune responses, including the modulation of antigen presentation and expansion of anti-inflammatory regulatory T cells. The maintenance of the host in this state provides a circulating reservoir of infective virus, increasing the statistical chance of viral transmission to a new host.

Once chronically infected with HBV or HCV, there is an astonishingly long period in most hosts, usually of decades, where there is no detriment to health. In some individuals attempted immune control of the virus by the host immune system over time drives liver inflammation and complications, such as liver cirrhosis or cancer. In these patients, there is a direct correlation between the degree of chronic inflammation (in this case the expression of the natural cytotoxicity receptor NKP46) and steadily worsening liver pathology. During chronic infection, HCV and HBV also employ strategies to escape from on-going host immunological attack by key adaptive immune cells such as cytotoxic CD8$^+$ T cells; for instance mutation of key viral epitopes, presented to these CD8$^+$ T cells by MHC class I molecules. Other diverse immune evasion strategies include interference with the signalling pathways required for production of pro-inflammatory cytokines, the up-regulation of inhibitory molecules such as PD-1 on virus-specific CD8$^+$ T cells and the expansion of CD4$^+$ T cells that can inhibit virus-specific CD8$^+$ T cells (reviewed in Park and Rehermann (Fig. 1.). These modifications can have a profound impact on the ability of the host to generate an immune response, or on underlying inflammatory conditions.

As the development of hepatitis virus liver-related illness usually takes many years and does not impact on reproductive fitness, the question arises: is there a benefit of viral immune manipulation on the human host population? One possibility is that the infected liver is less accommodating to other hepatotropic pathogens. Indeed studies have shown that patients with higher HBV viraemia have reduced *Plasmodium* spp. parasitaemia and exhibit asymptomatic malaria, characterized by decreased
inflammatory cytokine production. The young children most likely to become infected with HBV are particularly susceptible to malaria infection, illness and death, therefore viral dampening of this anti-malaria response would offer a clear selective advantage for the survival and transmission of HBV.

There are over 100 herpesviruses that infect vertebrate and invertebrate hosts. Eight commonly infect humans: herpes simplex virus types 1 and 2, varicella zoster virus, cytomegalovirus (CMV), Epstein–Barr virus (EBV), human herpesvirus 6, human herpesvirus 7 and Kaposi’s sarcoma-associated herpesvirus. All herpesviruses can establish latent infection within specific niches (e.g. nerve cells for herpes simplex virus, haematological cells for EBV, epithelial cells for CMV) and induce a systemic immune response. Immune control of these viruses, and the dynamics of viruses moving between latency and reactivation, results in fluctuating local and systemic inflammatory responses, which may result in injury and damage of infected tissues or a gradual deterioration of the immune system. A case in point is CMV infection of endothelial cells, where CMV-induced effector T cells cause endothelial cell damage and low-grade long-term vascular injury. CMV can have a profound impact on the T-cell compartment of the host immune system, driving bursts of functional CMV-specific memory CD8+ T-cell expansion during chronic infection. Although the establishment and maintenance of these inflated T-cell populations in adults is thought to be critical for the control of persistent viral infection, it is currently unclear how this process impacts on host immune responses to other pathogens and vaccines in otherwise healthy individuals. Immunosuppressive medical treatment of immunocompromised patients infected with CMV, can lead to virus-related clinical disease, such as CMV colitis, hepatitis or organ rejection. Underlying CMV infection or the opportunistic outgrowth of viral or bacterial commensal species results in loss of immune responsiveness or containment in these patients. The acquisition of CMV during early life has a profound impact on the immune cell subset composition of infants. Although controversial, some suggest that the natural acquisition of CMV infection by young children may prime and boost the adaptive immune system, moulding it for later life.

Herpesviruses have evolved an extraordinary ability to persist and escape immune detection by dedicating much of their large genomic capacity to subverting a diverse array of innate and adaptive immune responses. A major strategy for viral immune evasion is to target the initiation of the host immune response, by inhibiting host MHC class I antigen presentation of virus-specific epitopes to anti-viral cytotoxic CD8+ T cells. To counteract the possible increased natural killer cell killing of infected cells associated with loss of MHC class I, the machinery that alerts these cells is also dismantled by the virus (Fig. 1). However, during chronic Kaposi’s sarcoma-associated herpesvirus infection, the inhibition of antigen presentation by the virus can lead to the development of the endothelial tumour Kaposi’s sarcoma, particularly in immunocompromised patients.

For the vast majority of us who live harmoniously with these viruses, again the question arises: is there a fitness benefit for the host? Evidence from animal models
suggests that the presence of persistent latent (but not lytic) γ-herpesvirus infection can confer protection from lethal bacterial infection and lethal lymphoma challenge. Protection was associated with increased macrophage activation and the production of the antiviral cytokine interferon-γ. Latent viral infection could also significantly delay type 1 diabetes onset in mice by reducing antigen presentation of autoantigen to CD4+ T cells. Increases in the production of interferon-γ during latent viral infection may underlie protection from other types of inflammatory disease, as supported by epidemiological data demonstrating inverse associations between herpesvirus infection and 'type-2' allergic diseases. This skewing of the T helper type 1–type 2 balance will be considered in the following section focusing on the possible protective effects of chronic parasitic infection. Animal models have also shown that viral cytokine homologues, such as EBV IL-10 can provide some benefit to the host. EBV IL-10 can act on multiple cell types and inhibit cytokine synthesis by natural killer and T cells. The molecule is thought to play a critical role in the transformation of B cells, enabling time for the virus to establish latency. However, it has also been shown to inhibit collagen-induced arthritis, autoimmune diabetes and pancreatitis, and to improve survival following sepsis and graft acceptance when expressed or administered in vivo (Fig. 1). These examples demonstrate viral mutualistic symbiosis, as described above for other non-vertebrate eukaryotes.

The study of mutualistic symbiosis allows us to view millions of years of host–pathogen co-evolution. With increased movement of humans around the globe, we are also witnessing emerging new virus infections almost annually, often derived from animal reservoirs. Recognized in the 1980s, HIV has already provided evidence of pathogen-driven selection. Natural elite controllers are found in ~3/1000 of untreated HIV-infected individuals and are defined by stable CD4+ T-cell count with very low viral loads; these patients demonstrate superior anti-viral CD4+ T-cell and cytotoxic CD8+ T-cell responses. If effective anti-retroviral treatment was not available, it seems inevitable that pathogen-driven natural selection would favour these elite controllers, increasing the population frequencies of beneficial genetic polymorphisms such as HLA-B27, HLA-B51 and HLA-B57. Polymorphisms such as HLA-B27 also promote CD8+ T-cell clearance of HCV but are strongly linked to development of the autoimmune disease ankylosing spondylitis. Interestingly, some suggest that Plasmodium falciparum infection may have contributed to negative selection of this gene, due to the greater susceptibility of patients expressing this allele to severe forms of malaria. Genetic selection, the moulding of our immune response and subsequent susceptibility to disease, has occurred as a result of ancient long-standing infections by chronic pathogens, those causing malaria, leprosy, as well as parasitic worms (discussed in the next section).

**Parasites**

Helminths affect over one billion people worldwide, mostly within developing regions, such as sub-Saharan Africa, South America and India. Although new epidemiological studies are required, a systematic review in 2011 demonstrated that soil-transmitted helminths are also prevalent in high-income countries. Helminth infections have co-evolved with man and evidence suggests that in a similar manner to chronic viral infections (discussed in the previous section), they have provided selective pressure on the genetic make-up of the host. Helminth infections are acquired in childhood; however, in high-income countries zoonotic helminth infections of adults from cats and dogs are most common. Infection can cause diarrhoea, abdominal pain, weakness and anaemia and contributes to 14 million disability-adjusted life-years (or the cumulative number of years lost to ill-health, disability or early death). For orally transmitted helminths, mortality is rare and infection is often asymptomatic; most patients exhibiting low worm burden and limited clinical pathology.

Although gastrointestinal and intravascular helminth infections are reported to have some beneficial effects on inflammation-induced pathology in response to co-infection with other parasites, bacterial pathogens or viral infections, it can also impair protective immunity to concurrent parasite infections, promoting anaemia and liver pathology following malaria infection, exacerbating Citrobacter rodentium infection and associated bacterial-induced colitis and aggravating virus-related liver disease. This parasite impairment of host immunity has enormous health burden implications, particularly when immune responses to the biggest killers in the developing world, i.e. HIV, tuberculosis and diarrhoeic infections are affected. A number of mechanisms of immune suppression of co-infections are at play here, including the impairment of mucosal mastocytosis, the ablation of protective CD8+ T-cell responses, the induction or alteration of regulatory T-cell subsets and the alternative activation of colonic macrophages (Fig. 2).

Apart from an impact on immune responses to primary infection, the presence of chronic parasite infection in endemic areas has important implications for vaccination in the developing world. Epidemiological studies have demonstrated that human helminth infections can impair immune responses to tetanus toxoid and cholera toxin B in endemic areas. In murine and large animal models, helminth infection reduces the immune response to malaria and Salmonella vaccinations. As described previously, and in common with virus-induced immune
suppression, these effects are related to the production of regulatory cytokines such as IL-10 or the induction of regulatory T cells during chronic parasite infection.

A number of chronic parasites, including *Schistosoma haematobium*, *Opisthorchis viverrini* and *Clonorchis sinensis*, are also classified as Group 1 carcinogens, presenting a pertinent health challenge in developing regions. In parasite endemic regions, infection with *Schistosoma mansoni* and *Schistosoma japonicum* resulted in schistosomal colitis and was linked to increased bladder and cervical cancer. Studies in vitro have shown that the production of signature cytokines associated with murine *Heligmosomoides polygyrus* infection or *S. mansoni* egg administration promoted the replication of a herpesvirus that drives cancer (Kaposi’s sarcoma) and recent epidemiological studies associated soil-transmitted helminth infection with an increased prevalence of human papillomavirus (a major cause of cervical cancer). In mouse models, infection with the gastrointestinal helminth *H. polygyrus* substantially reduced the type 1 inflammatory response associated with *Helicobacter pylori* infection and attenuated gastric atrophy, a pre-malignant lesion. Infection with the extraintestinal tapeworm *Taenia crassiceps* reduced the development of colitis-associated tumours in a murine model of colorectal cancer. This effect was associated with increased expression of the type 2 cytokine IL-4 and with alterations in innate immunity, including macrophage alternative activation, neutrophil attraction and the recruitment of inflammatory monocytes.

In a similar manner to chronic viral infections, helminths have evolved potent mechanisms to regulate the host immune response, in order to ensure their long-term survival. As well as notable effects on specific anti-parasite responses, helminth immune regulation is proposed to exert mutualistic symbiosis, similar to the chronic viral infections discussed in the previous section, to further benefit the host – by suppressing responses to a number of allergens and autoantigens. Numerous studies have employed murine models of inflammatory disease to demonstrate that live parasite infection can protect against inflammatory disorders through immunomodulatory mechanisms including the activation of regulatory T cells or the production of IL-10. However, the immune-regulatory pathways that live helminths employ to modulate inflammatory disease are multi-faceted, impacting on B cells, macrophages, innate immunity and through alterations to intestinal microbiota and their metabolites.

In epidemiological studies, the story is more complex. Some studies have shown clear protection against allergen skin test reactivity in individuals infected with intestinal helminth infections such as *Ascaris lumbricoides*, *Trichuris trichiura*, hookworm and schistosomiasis. This protection from pathology is associated with helminth-induced polarization of the inflammatory cytokine response, in a similar manner to chronic viral infections (as discussed in the previous section). A correlation between parasite infection and improvements in multiple sclerosis was associated with increased frequencies of

---

**Figure 2.** The good (light) and bad (dark) side of chronic parasite infection. Chronic parasite infection can alter the commensal flora of the gut, resulting in reduced airway inflammation/allergy and inflammatory bowel disease. Parasite transforming growth factor-β homologues (pTGF-β) released into the host can promote regulatory T (Treg) cell expansion and up-regulation of programmed cell death protein 1 (PD-1), which inhibit CD4+ T-cell expansion and inflammatory cell production, resulting in reduced autoimmunity and allergy. Infection also promotes interleukin-10 (IL-10) production in the host, which can also promote Treg and reduce inflammation. Some helmint infections can promote the expansion of T cells producing IL-22 (Th22 cells), which are able to promote homeostasis of the gut epithelial lining, reducing inflammatory bowel disease. Finally, infection is also able to promote the formation of B cells, which can regulate inflammatory disorder such as asthma (regulatory B cells). On the bad side, parasite infection promotes Treg cells, which can reduce the efficacy of vaccines and the immune response to other infections. Here, IL-10 produced in the host in response to infection can also promote these Treg cells. Infection with parasites can ablate protective CD8+ T-cell responses against co-infections such as *Toxoplasma gondii*. The alternative activation of macrophages promoted by parasite infection can also impair host protection against concurrent bacterial infection.
CD4+ CD25+ Foxp3+ T cells and increased cellular production of the immune-regulatory cytokines IL-10 and transforming growth factor-β. Resolution of colitis in an individual who infected himself with T. trichiura was associated with an increase in IL-22-producing CD4+ cells. Interestingly, prior parasite infection could subdue subsequent immune responses in the long-term; both increased atopy and eczema were recorded in patients from a parasite endemic region that were treated in a long-term intervention study using the antihelminthic ivermectin. Use of the antihelminthics albendazole and praziquantel during pregnancy was also associated with an increase risk of eczema in infancy, suggesting that in utero helminth exposure may programme and prime the host immune system of the offspring. These studies clearly demonstrate that helminths can mould the genome of the host, similar to the chronic viral infections discussed in the previous section. Perhaps the best example of this for helminth infections is the selection of sickle cells traits, which confer resistance to malaria in endemic regions.

Live helminths are currently being employed in a number of clinical trials in efforts to alleviate allergic and autoimmune disorders. Successful trials include the treatment of patients with inflammatory bowel disease with eggs from the porcine whipworm Trichuris suis. However, not all trials using this strategy have had such a profound outcome, as evidenced by repeated treatment of patients exhibiting grass pollen-induced allergic rhinitis with T. suis ova. The effectiveness of using parasitic helminth infections to treat inflammatory disorders is called into question in a recent review. This publication discusses the limitations of our current understanding of host–parasite interactions and cites evidence of causal associations between helminth infections and inflammatory disorders. Recent reviews have also revealed the limitations of human studies in poor-resource settings, and indeed the consensus calls for the identification of helminth-derived molecules of therapeutic potential and the use of animal models, alongside appropriately controlled clinical trials, to test these novel treatments of inflammatory disease.

Some progress has already been made on this front; individual helminth-secreted products from the human hookworm Necator americanus, the filarial nematode Acanthocheilonema viteae and the marine gastrointestinal helminth H. polygyrus all suppressed rodent models of inflammatory disease, including arthritis, allergy and asthma. Each of these parasite-derived products has a unique capacity to modulate the host immune system at many levels, including suppression of mast cell responses, dampening the activation of inflammatory T cells by dendritic cells and by promoting the induction of regulatory T cells. Our increasing understanding of helminth modulation of immune function, has also led to the proposal that helminth-treated populations of cells, such as macrophages, be used in therapeutic applications for inflammatory diseases in humans. These results warrant further studies in animal models and possible clinical trials to determine the efficacy of these findings in humans.

In conclusion, both chronic viral and parasite infections can have both a beneficial and detrimental impact on the host immune system. A consensus on one conserved mechanism of immune suppression has not been reached, although this is mainly due to the complexity of the immune response, the tissue specificity of infection and the underlying health status of the individual. As for chronic viral infections, intestinal parasites have moulded our genome and have an intimate bi-directional relationship with the host. Our increasing understanding of host–pathogen interactions and the complexity of our micro- and macro-biome will enhance our ability to break the bad consequences of chronic infection and make good through tailored treatment of an individual with an inflammatory disorder, or the development of strategies that increase vaccine efficacy and limit infection-associated tumour prevalence, in endemic regions.

Disclosures

There are no competing interests that might have influenced this manuscript.

References

1 Virgin HW. The virome in mammalian physiology and disease. Cell 2014; 157:142–50.
2 Tamburini S, Shen N, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nat Med 2016; 22:713–22.
3 Godkin A, Jeanguet N, Thursz M, Openshaw P, Thomas H. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-virion patients. Eur J Immunol 2001; 31:1438–46.
4 Jankovic D, Kugler DG, Sher A. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal Immunol 2010; 3:239–46.
5 Oakley OR, Garvy BA, Humphreys S, Qureshi MH, Pomeroy C. Increased weight loss with reduced viral replication in interleukin-10 knock-out mice infected with murine cytomegalovirus. Clin Exp Immunol 2008; 154:155–64.
6 Rikland Y, Piccirillo CA, Mendez S, Shervach EM, Sacks DL. CD4+ CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420:502–7.
7 Seifarth W, Frank O, Zeilfelder U, Spiess B, Greenwood AD, Hehlmann R et al. Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray. J Virol 2005; 79:341–52.
8 Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 2009; 138:30–50.
9 Xu P, Chen F, Mannan JP, Feldman T, Sumner LW, Roossinck MJ. Virus infection improves drought tolerance. New Phytol 2008; 180:911–21.
10 Oliver KM, Degnan PH, Hunter MS, Moran NA. Bacteriophages encode factors required for protection in a symbiotic mutualism. Science 2009; 325:992–4.
11 Thomas HC, Lemon S, Zuckerman AJ. Viral Hepatitis, 3rd edn. Oxford, UK: Wiley-Blackwell, 2008.
12 Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:495–506.
13 Ferrari C, Penna A, Bertolotti A, Valli A, Antoni AD, Giuberti T et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145:3442–9.
Breaking bad with chronic infection

14 Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005; 79:9369–80.
15 Keynan Y, Card CM, McLaren PJ, Dawood MR, Kasper K, Fowke KR. The role of regula-
16 tory T cells in chronic and acute viral infections. Clin Infect Dis 2008; 46:1056–62.
17 Pembroke T, Jordan A, Jones E, Hills RK, Wang FC, Gallimore AM et al. The para-
18 dox of Nkx6-1: natural killer cell drivers of severe hepatitis C virus-induced pathol-
19 ogy but in vivo resistance to interferon α treatment. Gut 2014; 63:515–24.
18 Timm J, Lauer GM, Kavanagh DG, Shridan I, KimAY, Lucas M et al. CD8 epitope escape and rever-
19 sion in acute HCV infection. J Exp Med 2004; 200:1593–604.
19 Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014; 40:13–24.
20 Andrade BB, Santos CJ, Camargo LM, Souza-Neto SM, Rese-Filho A, Cláudio J et al. HLA-B27 and ankylosing spondylitis.
21 Karlsson EK, Kwiatkowski DP, Sabeti PC. Natural selection and infectious disease in
22 Africa. Science 2006; 312:1354–8.
23 Hsu DH, de Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, de Vries J. Cytokine inter-
24 actions in HIV-1 infection: the role of IL-10. Immunol Rev 2000; 174:142–59.
24 Klenerman P, Oxenius A. T cell responses to cytomegalovirus.
25 Ploegh HL. Viral strategies of immune evasion.
26 Snyder CM, Cho KS, Bonnett EL, van Dommelen S, Shellam GR, Hill AB. Memory
27 T cells in HIV-infected individuals: are they controlling HIV viral load?
28 Huygens A, Dauby N, Vermijlen D, Marchant A. Immunity to cytomegalovirus in
29 early life. Front Immunol 2014; 5:532.
30 Smith KA, Efstathiou S, Cooke A. Murine gammaherpesvirus-68 infection alters self-anti-
31 genicity A review supporting the hypothesis.
32 Slobedman B, Barry PA, Spencer JV, Avdic S, Abendroth A. Virus-encoded homologs
33 of tumor necrosis factor α (TNFα) in Trichinella spiralis: implications for immunity to blood-stage malaria by concurrent nematode infec-
34 tion. J Infect Dis 2009; 199:1528–35.
35 Su Z, Segura M, Morgan K, Loredo-Osti JC, Stevenson MM. Impairment of protective immunity to blood-stage malaria by concurrent nematode infection. Infect Immun 2005; 73:3531–9.
36 Behnke JM, Wakelin D, Wilson MM. Trichinella spiralis: delayed rejection in mice concurrently infected with Nematodirus spumoides. Parasitology 1977; 75:71–8.
37 Behnke JM, Wakelin D, Wilson MM. Trichinella spiralis: delayed rejection in mice concurrently infected with Nematodirus spumoides. Exp Parasitol 1978; 48:121–30.
38 Hartgers FC, Obeng BB, Kruize YG, Dijkstra A, McCall M, Sauerwein RW et al. Responses to malarial antigens are altered in helminth-infected children. J Infect Dis 2009; 199:1528–35.
39 Helmy H. Gastrointestinal nematode infection exacerbates malaria-induced liver pathol-
40 ogy. J Immunol 2009; 182:5663–71.
40 Chen CC, Louie S, McCormick B, Walker WA, Shi HN. Concurrent infection with an intestinal helminth parasite impairs host resistance to enteric Vibrio cholerae: a possible mechanism for severe cholera. J Immunol 2007; 179:4732–35.
41 Colman R, Blackburn DJ. Risk factors in the development of Kapoor’s sarcoma. AIDS 2006; 20:167–9.
42 Benton J, Wess X, Nathans J, Blumberg B. Helper T cell responses to cytomegalovirus.
43 Lerner PA, O’Neill HC, Sato K. Effect of infection with Nematodirus spumoides. J Helminthol 2006; 80:95–105.
44 Fox JG, Beck P, Dangler CA, Whary MT, Wang TC, Shi HN et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces Helicobacter-induced gastric atrophy. Nat Med 2000; 6:536–42.
45 Scher S, Krempel C, Kallfass C, Frey S, Jakob T, Mohau G et al. S. mansoni bolsters anti-viral immunity in the murine respiratory tract. PLoS One 2014; 9:e112469.
46 Colwell DA, Wesscot RB. Prolongation of egg production of Nippostrongylus brasili-
66 anis in mice concurrently infected with Nematodirus spumoides. J Parasitol 1973; 59:216.
47 Jenkins SN, Behnke JM. Impairment of primary expulsion of Trichinella muris in mice concurrently infected with Nematodirus spumoides. Parasit Vectors 2015; 8:155.
48 Hsu DH, de Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, de Vries J. Cytokine inter-
actions in HIV-1 infection: the role of IL-10. Immunol Rev 2000; 174:142–59.
49 Jenkins SN, Behnke JM. Impairment of primary expulsion of Trichinella muris in mice concurrently infected with Nematodirus spumoides. Parasit Vectors 2015; 8:155.
50 Behnke JM, Wakelin D, Wilson MM. Trichinella spiralis: delayed rejection in mice concurrently infected with Nematodirus spumoides. Exp Parasitol 1978; 48:121–30.
51 Hartgers FC, Obeng BB, Kruize YG, Dijkstra A, McCall M, Sauerwein RW et al. Responses to malarial antigens are altered in helminth-infected children. J Infect Dis 2009; 199:1528–35.
52 Su Z, Segura M, Morgan K, Loredo-Osti JC, Stevenson MM. Impairment of protective immunity to blood-stage malaria by concurrent nematode infection. Infect Immun 2005; 73:3531–9.
53 Norland GS, Ayodo G, Abeya I, Hodges JS, Rolfes MA, John CC. Decreased prevalence of anemia in highland areas of low malaria transmission after a 1-year interruption of transmission. Clin Infect Dis 2012; 54:78–87.
54 Helmy H. Gastrointestinal nematode infection exacerbates malaria-induced liver pathol-
ogy. J Immunol 2009; 182:5663–71.
55 Chen CC, Louie S, McCormick B, Walker WA, Shi HN. Concurrent infection with an intestinal helminth parasite impairs host resistance to enteric Vibrio cholerae: a possible mechanism for severe cholera. J Immunol 2007; 179:4732–35.
56 Colman R, Blackburn DJ. Risk factors in the development of Kapoor’s sarcoma. AIDS 2006; 20:167–9.
57 Benton J, Wess X, Nathans J, Blumberg B. Helper T cell responses to cytomegalovirus.
58 Lerner PA, O’Neill HC, Sato K. Effect of infection with Nematodirus spumoides. J Helminthol 2006; 80:95–105.
Infections and allergy et al. Heligmosoides polygyrus infection can inhibit colitis through direct interaction with innate immunity. J Immunol 2010; 185:3184–9.

79 Zais MM, Rapin A, Lebon L, Dubey LK, Mosconi I, Sarter K et al. The intestinal microbiota contributes to the ability of helminths to modulate experimental allergic inflammation. Immunity 2015; 43:989–1010.

80 Ramanan D, Bowcutt R, Lor SC, Tang MS, Kaurz DD, Ding Y et al. Helminth infection promotes colonization resistance via type 2 immunity. Science 2016; 352:608–12.

81 Cooper PJ, Chico MI, Rodrigues LC, Ordonnez M, Strachan D, Griffin GE et al. Reduced risk of atopy among school-age children infected with hookworm parasites in a rural area of the tropics. J Allergy Clin Immunol 2003; 111:985–1000.

82 Feary J, Birtton J, Leonard-Ree J. Atopy and current intestinal parasite infection: a systematic review and meta-analysis. Allergy 2011; 66:569–78.

83 Corrales I, Fares M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 2007; 61:97–108.

84 Broadhurst MJ, Leung JM, Kashyap V, McMune JM, Mahadevan U, McKerrow JH et al. IL-22+ CD4+ T cells are associated with therapeutic Trichuris trichura infection in an ulcerative colitis patient. Sci Transl Med 2010; 2:68ra88.

85 Leung JM, Davenport M, Wolf ME, Wiens KE, Abdi WM, Pokes MA et al. IL-22-producing CD4+ cells are depleted in actively inflamed colitic tissue. Mucosal Immunol 2014; 7:124–33.

86 Endara P, Vaca M, Chico ME, Erazo S, Oviedo G, Quinzo I et al. Long-term periodic anthelmintic treatments are associated with increased allergen skin reactivity. Clin Exp Allergy 2010; 40:1669–77.

87 Mpairwe H, Webb EL, Muhangi I, Ndiruza I, Akihade D, Nampijja M et al. Anthelmintic treatment during pregnancy is associated with increased risk of infantile eczema: randomised-controlled trial results. Pediatr Allergy Immunol 2011; 22:385–92.

88 Ndiruza I, Mpairwe H, Webb EL, Mwa PA, Nampijja M, Muhangi I et al. Impact of anthelmintic treatment in pregnancy and childhood on immunisations, infections and eczema in childhood: a randomised controlled trial. PLoS ONE 2012; 7:e50325.

89 Aidoo M, Terlouw DJ, Kockaz MS, McElroy PD, ter Kuile FO, Kariuki S et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359:1311–2.

90 Khan AR, Fallon PG. Helminth therapies: translating the unknown unknowns to known knowns. Int J Parasitol 2013; 43:293–9.

91 Summers RW, Elliott DE, Urban Jr Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomised controlled trial. Gastroenterology 2015; 148:825–32.

92 Summers RW, Elliott DE, Urban Jr Jr, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn’s disease. Gut 2005; 54:87–90.

93 Bager P, Arwed J, Reinsberg S, Wohlfahrt J, Poulsen LK, Westergaard T et al. Trichuris suis ova therapy for allergic rhinitis: a randomised, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 2010; 125:123–130 e121–2.

94 Briggs N, Weatherhead J, Sasyi KJ, Horiz PJ. The Hygiene hypothesis and its inconvenient truths about helminth infections. PLoS Negl Trop Dis 2016; 10:e0004944.

95 Wammes LJ, Mpairwe H, Elliott AM, Yazdanbakhsh M. Helminth therapy or elimination: epidemiological, immunological, and clinical considerations. Lancet Infect Dis 2014; 14:1150–62.

96 Navarro S, Pickering DA, Ferreira IB, Jones L, Ryan S, Troy S et al. Hookworm recombinant protein promotes regulatory T cell responses that suppress experimental asthma. Sci Transl Med 2016; 8:362ra143.

97 Hamnett MM, Meldrein AJ, Harnett W. The therapeutic potential of the filarial nematode-derived immunomodulator, ES-62 in inflammatory disease. Clin Exp Immunol 2010; 159:256–67.

98 McSorley HJ, Blair NF, Smith KA, McKenzie AN, Maizels RM. Blockade of IL-33 RI-mediated mast cell responses by ES-62, a product of parasitic Helminth-therapy master of regulation. Infect Immun 2010; 78:4013–5.

99 Summers RW, Elliott DE, Urban Jr Jr, Thompson RA, Weinstock JV. Trichuris suis therapy in Crohn’s disease. Gut 2005; 54:87–90.

100 Grainger JR, Smith KA, Hewitson JP, McSorley HJ, Harcus Y, Filbey KJ et al. Trichuris suis ova therapy for allergic rhinitis: a randomised, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 2010; 125:123–130 e121–2.

101 Steinfelder S, O’Regan NL, Hartmann S. Diplomatic assistance: can helminth-modulated practices in airway allergy. J Allergy Clin Immunol 2007; 119:203–9.

102 McSorley HJ, Blair NF, Smith KA, McKenzie AN, Maizels RM. Blockade of IL-33 RI-mediated mast cell responses by ES-62, a product of parasitic Helminth-therapy master of regulation. Infect Immun 2010; 78:4013–5.